Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY EXTENSION
2017-003310-74Phase 3Unknown
- Sponsor
- Myovant Sciences
- Start
- Nov 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tissue-plasminogen activator, estradiol and norethisterone acetate in Fibromyoma (LM) and hypermenorrhea, sponsored by Myovant Sciences. Primary endpoint: Proportion of women achieving or maintaining menstrual blood loss response at the last 35 days of treatment. Status: unknown.
02
Drugs
tissue-plasminogen activatorestradiolnorethisterone acetate
03
Conditions
Fibromyoma (LM)hypermenorrhea
Beyond the preview
Go deeper on 2017-003310-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003310-74.